Ocular toxicity of high-dose intravenous desferrioxamine.
about
Oral deferiprone for iron chelation in people with thalassaemiaOral deferiprone for iron chelation in people with thalassaemiaDesferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemiaReversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPAOxygen toxicity, oxygen radicals, transition metals and diseaseOcular changes in patients undergoing long-term desferrioxamine treatmentMultiple transfused thalassemia major: ocular manifestations in a hospital-based population.Contrast sensitivity in patients with Beta-thalassemia major and sickle cell disease under regular transfusions and treatment with desferrioxaminePractical management of iron overload.Free radical mediated cytotoxicity of desferrioxamine.Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.Toxicology of sensory systems: a perspective.β-Thalassemia and ocular implications: a systematic review.Desferrioxamine-related ocular toxicity: a case report.Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.Haemochromatosis presenting as congestive cardiac failure.Macular vitelliform lesion in desferrioxamine-related retinopathy.Drug disposition in the mammalian eye and brain: a comparison of mechanisms.Current approach to iron chelation in children.Retinal abnormalities in β-thalassemia major.Recent developments in aluminum toxicology.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.The use of chelating agents in the treatment of aluminum overload.Safety profiles of iron chelators in young patients with haemoglobinopathies.Iron-chelating therapy.Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models.Risks of parenteral deferoxamine for acute iron poisoning.Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findingsDeferoxamine (Desferal)-induced ocular toxicity.Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.Quantitative evaluation of the retinal venous tortuosity in chronic anaemic patients affected by beta-thalassaemia major.Citric, malic and succinic acids as possible alternatives to deferoxamine in aluminum toxicity.Comparative aluminium mobilizing actions of several chelators in aluminium-loaded uraemic rats.Neurophysiologic study of beta-thalassemia patients.Survival and disease complications in thalassemia major.Desferrioxamine administered intravenously by infusion causes a reduction in the electroretinogram in rabbits anaesthetized with urethane.Comparative Effects of Several Chelating Agents on the Toxicity, Distribution and Excretion of AluminiumIn Vitro Screening of Iron Chelators Using Models of Free Radical Damage
P2860
Q24200309-2E685595-E7B3-46A2-9C06-FAD3E6063418Q24244045-D588E856-27F7-4243-842C-507060A056A1Q24245574-1A484AE7-0563-409F-8BA6-A6077C489DB4Q28360112-561ED424-AC87-4B79-8A30-53B9C876F3E1Q29615096-CDF177CC-A029-44A1-A748-FDE6FF3EF00BQ33643753-6FC782A1-1BF6-4FEE-A550-9F444B65B4DEQ33788767-191A6266-EBD6-4136-9041-DC66C423B6C2Q34152812-06B333F6-2CD6-423F-838F-6E7CBFAFF7CCQ34434629-3B7236EC-9EC2-4C3E-9095-2A3292BA4CCAQ35158610-028A52C1-1BDD-4363-9F9D-60D7F40F99C9Q35200434-B2F83049-C569-4A27-B53D-D314E06C1742Q35273552-A5D3F589-63A9-49F2-B2C3-91A948274E99Q36070750-D6AE2D84-799E-4D19-87AA-EB04F66AE126Q36234619-828B9D5D-4B24-4E67-9EC5-2E65A62B2053Q36518462-68053C4E-5C02-433D-994E-16CED6CB75D3Q36815489-C9A13608-C59A-4BA5-A160-75C1184A40ABQ36948656-DB6D75C5-9344-49D2-BE27-E649E7E9921DQ37238136-A46F397D-FF44-468B-82D5-E13208ED0057Q38197269-E078ABCF-50B0-452B-8D59-829DAB5A6ECBQ38577858-890AC4FD-C4E6-4928-B1D8-ABF63545552AQ38620775-21DD3FD6-A20A-4223-A563-8301411C920DQ38650293-3DEC7447-E522-47E2-9693-E111ADBEEFD2Q38775147-F57F46D1-0C06-40C1-A6E1-935109F1DE10Q39022073-313F4A9D-2F83-49BF-AFEF-63652471C14DQ39581560-BCE40CF6-AA0A-4533-AEEE-B0BD64B93AB9Q39618652-B166563A-84E4-4E49-9229-FF8602ECB9F5Q41107649-BD8A1598-D044-499C-B918-3153AE49D8F6Q41779524-E3ED28A3-3A63-4AAC-9D19-5BF3B5E914F1Q41880406-37AC2F4D-0B4B-48E8-BD56-C1AFBC8576EDQ41905204-96475D17-C027-4000-8B58-228AEBE224D1Q42209452-BF1FBA7C-877E-4D84-BA79-3892D9A3212EQ42835886-57A092BF-A59D-455E-9096-648F632705B4Q44425422-34B23564-2C9A-472A-B67C-B30B76AA8572Q48128782-EC1906D9-0115-4241-A9D9-4A7043F4750FQ48186024-2301556F-356B-44BE-A5B2-CB96AE602997Q50527880-576E6398-DE29-4D57-A207-F741574A9C6AQ50876031-2F03EBFC-930B-480E-BE7C-06988BBE2C01Q51806844-2D68FFE6-34CE-4150-B6AE-4E00CD9D3B82Q57266664-74EF8C22-AADF-4E13-BA0A-0C6A8F82A859Q58487654-CB0E4D85-4AC9-4A33-A3F3-9C88FF9E50D1
P2860
Ocular toxicity of high-dose intravenous desferrioxamine.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Ocular toxicity of high-dose intravenous desferrioxamine.
@en
Ocular toxicity of high-dose intravenous desferrioxamine.
@nl
type
label
Ocular toxicity of high-dose intravenous desferrioxamine.
@en
Ocular toxicity of high-dose intravenous desferrioxamine.
@nl
prefLabel
Ocular toxicity of high-dose intravenous desferrioxamine.
@en
Ocular toxicity of high-dose intravenous desferrioxamine.
@nl
P2093
P1433
P1476
Ocular toxicity of high-dose intravenous desferrioxamine.
@en
P2093
E R Huehns
J L Hungerford
M H Miller
R E Marcus
S C Davies
P304
P356
10.1016/S0140-6736(83)90170-8
P407
P577
1983-07-01T00:00:00Z